Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: These are a few

to rush into a M&A program, which loses $20,000,000 of shareholder assets in 18 months, without proper due diligence?

If so, this could be serious.

Why isn't every shareholder asking every PTSC director this question?

Share
New Message
Please login to post a reply